Clinical Trial Update: Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Stage II-IIIa urothelial carcinoma evaluating pre-operative nivolumab with or without relatlimab. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Status: RECRUITING